GlaxoSmithKline Consumer Healthcare Announces Availability of Nicorette® mini Lozenge

GlaxoSmithKline Consumer Healthcare Announces Availability of Nicorette® mini Lozenge

PARSIPPANY, N.J., April 27, 2015 /PRNewswire/ -- GlaxoSmithKline Consumer Healthcare (GSKCH) today announced 2 mg and 4 mg Nicorette® mini Lozenge is now available at most retail shelves in the US following a supply shortage.

In February 2014, GSKCH voluntarily recalled all nicotine lozenges from warehouses and distributors manufactured at a site in Aiken, S.C. after manufacturing issues affecting some batches were detected. In some cases, the lozenges were larger or smaller than GSKCH's manufacturing standards. After a comprehensive assessment and complex testing process to correct manufacturing issues and improve quality measures, production of Nicorette mini Lozenge has resumed.

"The safety and well-being of our consumers is our number one priority and we did not compromise on the somewhat lengthy corrective actions that needed to be taken," said Sue Kelsey, GlaxoSmithKline Consumer Healthcare Marketing Director, Wellness & Skin Health Brands. "We understand what a life-changing event stopping smoking can be and, at the same time, how incredibly difficult it can be to get there. For those looking for help, we hope that the return to market of Nicorette mini Lozenge and our online information can help to provide the tools and inspiration to get smokers towards their goals."  

Nicorette mini Lozenge is a mini-sized stop-smoking lozenge that can double smokers' chances of quitting. Nicorette mini Lozenge comes in a discreet pocket-size vial so smokers can have it on hand to help address craving and withdrawal symptoms associated with quitting smoking.

Other GSKCH FDA-approved nicotine replacement therapy (NRT) products, include Nicorette® gum and NicoDerm® CQ®, which have helped millions fight the battle against smoking.[i] Large 2 mg and 4 mg Nicorette Lozenge is expected to be back on shelves later in 2015.  Consumers can also look for NicoDerm CQ in new packaging.

GSK Consumer Healthcare is committed to providing consumers with scientifically proven products. We have been assisting consumers in their quit journey for almost 20 years through our nicotine replacement therapy (NRT) products and have helped millions fight the battle against smoking. Data from 117 clinical trials involving more than 50,000 smokers have established a long-term safety and efficacy profile for NRT.[ii]

For helpful information about quitting and to connect with other smokers interested in quitting, smokers can sign up for our email support program at

[i] based on sales data[ii] The Cochrane Library. Nicotine replacement therapy for smoking cessation. 2012.

About GSK Consumer Healthcare

GSK Consumer Healthcare is one of the world's largest consumer healthcare companies.  Our purpose is to help more people around the world to do more, feel better and live longer with everyday healthcare products.  We have a heritage that goes back over 160 years.  We own some of the world's best loved healthcare brands, including Sensodyne®, Theraflu®, Excedrin®, Nicorette® and NicoDerm®CQ®, Flonase®, and TUMS®.These brands are successful in over 100 countries around the world because they all show our passion for quality, guaranteed by science. They are inspired by the real wants and needs of the millions of people who walk into pharmacies, supermarkets, market stalls and go on-line all over the world every day, and choose us first.

Our goal is to build a global, growing business we call a Fast Moving Consumer Healthcare (FMCH) company, dedicated to everyday healthcare with all of the scientific expertise and quality guarantees that demands, working at the speed and with the genuine consumer understanding the modern world expects.

About GlaxoSmithKline

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For company information visit:

SOURCE GlaxoSmithKline Consumer Healthcare